Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 3,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapsed/Refractory Clear all

Conditions: Low Risk Myelodysplastic Syndromes
Interventions: R906289 Monosodium (R289 Na); Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 10 more

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Disulfiram, Fludarabine, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
Interventions: dasatinib, diagnostic laboratory biomarker analysis, pharmacological study, cyclosporine; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Plasma Cell Myeloma
Interventions: isatuximab SAR650984, carfilzomib, dexamethasone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: San Francisco, California • Spartanburg, South Carolina

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: cytarabine, laromustine; Drug
Lead sponsor: Vion Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Pomalidomide; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma
Interventions: PHOX2B PC-CAR T Cells; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 1 Year and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer
Interventions: GSK1120212; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 12 more

Conditions: Lymphoma, T-Cell, Peripheral
Interventions: MK-3475, Copanlisib; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ondansetron, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 12
States / cities: Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more

Conditions: Neuroblastoma
Interventions: Tolcapone, Oxaliplatin; Drug
Lead sponsor: Giselle Sholler; Other
Eligibility: 0 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 6 more

Conditions: B-Cell Pediatric ALL
Interventions: Moxetumomab Pasudotox; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 7 more

Conditions: T-Cell Lymphoma
Interventions: Brentuximab vedotin, Pembrolizumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Boston, Massachusetts

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Duvelisib; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Tempe, Arizona • Hot Springs, Arkansas • La Jolla, California + 5 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab, Dexamethasone, Venetoclax; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Indianapolis, Indiana • Rochester, Minnesota • Wauwatosa, Wisconsin

Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, High-risk Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Advanced Myelofibrosis
Interventions: TH-302; Drug
Lead sponsor: Threshold Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Panitumumab; Biological
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
Interventions: Isatuximab SAR650984, dexamethasone, acetaminophen, ranitidine, diphenhydramine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Hackensack, New Jersey • Houston, Texas

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
Interventions: Gilteritinib, Vyxeos; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Mosunetuzumab, Patient Observation, Polatuzumab Vedotin, Positron Emission Tomography, Tisagenlecleucel; Biological · Procedure · Drug + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 95
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: herpes simplex thymidine kinase, ganciclovir; Biological · Drug
Lead sponsor: John Stoddard Cancer Center at Iowa Methodist Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Neuroblastoma
Interventions: Bevacizumab, Irinotecan and Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions: Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab, Pharmacological Study; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes, Myeloid Metaplasia, Lymphoma
Interventions: ridaforolimus; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 8
States / cities: Chicago, Illinois • St Louis, Missouri • New Brunswick, New Jersey + 5 more

Search by objective public record fields.

Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)

Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)